Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- BCT.TO
- Price
- 6.00
- Stock movement up
- +0.29 (5.08%)
- Company name
- Briacell Therapeutics Corp
- Exchange
- (TO ,
- Currency
- CAD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 217.88M
- Ent value
- 229.38M
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -30.90%
- 1 year return
- 61.73%
- 3 year return
- -23.64%
- 5 year return
- -12.94%
- 10 year return
- -14.67%
Last updated: 2025-04-12
DIVIDENDS
BCT.TO does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 36.31M |
| EPS (TTM) | -0.38 |
| FCF per share (TTM) | -2.74 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -35.27M |
| Net income (TTM) | -6.00M |
| EPS (TTM) | -0.38 |
| EPS (1y forward) | -1.28 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 935.69K |
| Net receivables | 15.23K |
| Total current assets | 5.53M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 6.20M |
| Accounts payable | 6.42M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 6.76M |
| Total liabilities | 12.44M |
| Shareholder's equity | -6.23M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -43.84M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -43.84M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -96.66% |
| Return on Invested Capital | 96.20% |
| Cash Return on Invested Capital | 703.28% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 5.74 |
| Daily high | 6.00 |
| Daily low | 5.74 |
| Daily Volume | 10K |
| All-time high | 596.10 |
| 1y analyst estimate | 20.00 |
| Beta | 1.82 |
| EPS (TTM) | -0.38 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 12 Jun 2025 |
Downside potential
Loading...
Downside potential data
| BCT.TO | S&P500 | |
| Current price drop from All-time high | -98.99% | -12.89% |
| Highest price drop | -99.91% | -56.47% |
| Date of highest drop | 28 Jan 2025 | 9 Mar 2009 |
| Avg drop from high | -86.38% | -11.07% |
| Avg time to new high | 421 days | 12 days |
| Max time to new high | 2917 days | 1805 days |
COMPANY DETAILS
Marketcap
217.88M
Marketcap category
Small-cap
Description
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Country
Canada
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
BriaPro is developing novel antibodies to B7-H3, a key cancer antigen and immune checkpointHighly expressed on the cell surfaces of both tumor and immune cells, B7-H3 is a promising anti-cancer target...
April 10, 2025
PHILADELPHIA and VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnol...
March 26, 2025
The Data Safety Monitoring Board (DSMB) identified no safety concerns, and recommended continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitor in metastatic bre...
March 20, 2025
After losing some value lately, a hammer chart pattern has been formed for BRIACELL THERAP (BCTX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate...
February 11, 2025
PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) (“BriaCell” or the “Company”), a clinical-stage biotech...
February 5, 2025
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...
February 5, 2025
BRIACELL THERAP (BCTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
February 5, 2025
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...
February 4, 2025
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...
February 3, 2025
Lung metastasis (from metastatic breast cancer) resolved - after only 2 months (4 doses) of treatment with Bria-OTS™ monotherapyNo toxicity related to the treatment; Patient remains on studyUnpreceden...
February 3, 2025
Next page